摘要
目的瑞马唑仑对全身麻醉下腹腔镜胆囊切除术安全性及有效性评价。方法选择荆门市第一人民医院行腹腔镜胆囊切除术的患者120例,按照随机数表法分为丙泊酚组(P组),瑞马唑仑组(R组),丙泊酚+氟马西尼组(P+F组),瑞马唑仑+氟马西尼组(R+F组),每组各30例。记录患者术前(T0)、插管即刻(T1)、气腹即刻(T2)和拔管即刻(T3)的血压及心率变化情况,记录患者术后苏醒时间以及不良反应发生率。结果两组患者在术前(T0)、插管即刻(T1)、气腹即刻(T2)和拔管即刻(T3)的血压及心率差异无统计学意义。与P组相比,R组药物注射痛、呼吸抑制及恶心呕吐的发生率明显降低(P<0.05)。与P组相比,R组苏醒时间明显延长,R+F组苏醒时间明显缩短(P<0.05);与R组相比,P+F组以及R+F组苏醒时间明显缩短(P<0.05)。结论瑞马唑仑诱导及维持在全身麻醉腹腔镜胆囊切除术中麻醉效果较好,患者生命体征平稳,镇痛效果佳,不良反应少。
Objective To evaluate the safety and efficacy of remimazolam in laparoscopic cholecystectomy under general anesthesia.Method A total of 120 patients who underwent laparoscopic cholecystectomy in our hospital were selected and divided into four groups according to random number table method:propofol group(group P),remimazolam group(group R),propofol+flumazenil according to group(P+F group),remimazolam+flumazenil group(R+F group),with 30 cases in each group.The changes of blood pressure and heart rate before operation(T0),immediately after intubation(T1),immediately after pneumoperitoneum(T2)and immediately after extubation(T3)were recorded,and the postoperative recovery time and incidence of adverse events were recorded.Result There were no significant differences in blood pressure and heart rate between the two groups at T0,T1,T2 and T3.Compared with group P,the incidences of drug injection pain,respiratory depression,nausea and vomiting in group R were significantly lower(P<0.05).Compared with group P,the recovery time of group R was significantly prolonged,and the recovery time of group R+F was significantly shortened(P<0.05).Compared with group R,the recovery time of group P+F and group R+F was significantly shortened(P<0.05).Conclusion Remimazolam induction and maintenance in general anesthesia laparoscopic cholecystectomy show good anesthesia effect.The patient’s vital signs are stable and the adverse events are rare.
作者
周玉
李姝霈
李涛
王婵
邵恳
杨昌明
Zhou Yu;Li Shupei;Li Tao;Wang Chan;Shao Ken;Yang Changming(Department of Anesthesiology,the First People’s Hospital of Jingmen,Jingmen 448000,Hubei,China)
出处
《中国医学前沿杂志（电子版）》
2022年第7期41-44,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
鄂皖科研基金。
